Tata Trusts has announced signing of an agreement with the US-headquartered biopharmaceutical company Gilead Sciences to explore collaboration to tackle the viral hepatitis in the country, a release stated.
Under the Memorandum of Understanding (MoU), both Tata Trusts and Gilead will form a joint program committee to implement activities related to prevention, awareness and education, testing and treatment of viral hepatitis.
"As part of our overall health strategy aimed at addressing communicable diseases in India, we look forward to partnering with Gilead to create unique models to reduce the prevalence of viral hepatitis," said Tata Trusts Managing Trustee, R Venkataramanan.
"Viral hepatitis presents a complex public health challenge in India, and by working in partnership and pooling our expertise, we hope to identify sustainable initiatives that can have a lasting impact on the burden of disease," added Gilead Executive Vice President, Commercial and Access Operations in Asia, Latin America and Africa, Corporate and Medical Affairs, Gregg Alton.
